Basilea Pharmaceutica
| Basilea Pharmaceutica Ltd.
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0011432447 |
| founding | 2000 |
| Seat | Basel , Switzerland |
| management | David Veitch (Chairman of the Management Board ) Domenico Scala ( Chairman of the Board of Directors ) |
| Number of employees | approx. 225 (2019) |
| sales | 134.4 million CHF (2019) |
| Branch | Pharma , research |
| Website | www.basilea.com |
The Basilea Pharmaceutica Ltd. is a biopharmaceutical company headquartered in Basel , Switzerland . It was from the 2000 F. Hoffmann-La Roche spun and since March 2004 as a separate company on the Swiss Stock Exchange listed . At the end of February 2018, its market capitalization was almost 822 million Swiss francs.
Field of activity
The company 's research and development activities focus on drugs for the treatment of resistant bacterial and fungal infections, as well as on dermatological drugs .
Products
Basilea's products target previously inadequately treatable diseases . The company's product portfolio includes the following products:
Alitretinoin , an oral retinoid used to treat chronic hand eczema that is unresponsive to topical steroids. Alitretinoin was sold under the brand name Toctino®. In June 2012 Basilea entered into a global agreement with Stiefel, a GSK company. Stiefel receives the exclusive worldwide rights for Toctino® as well as a know-how license and takes over Basilea's existing Toctino® distribution agreements.
Ceftobiprole , a cephalosporin - antibiotic (Trade Zevtera® / Mabelio®) is a bakterienabtötendes, intravenously administrable cephalosporin broad-spectrum antibiotic that gram-positive and gram-negative pathogens covered, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas spp, frequent pathogens of. pneumonia acquired in hospital. It is approved in certain European countries for the treatment of adults with hospital-acquired pneumonia (with the exception of ventilator-associated pneumonia) and community-acquired pneumonia.
Isavuconazole , (ingredient isavuconazonium sulfate; trade name Cresemba ) is a broad-spectrum antifungal agent that is under development, can be administered once a day and is available in both intravenous and oral dosage forms. It is used for the treatment of invasive, life-threatening fungal infections that predominantly occur in immunocompromised patients , for example in cancer patients undergoing chemotherapy. Isavuconazole was jointly developed with Astellas Pharma Inc. Basilea holds full rights to isavuconazole in markets outside of the US and Canada; in these two countries the exclusive rights are held by Astellas. In July 2017, Basilea and Pfizer announced that Pfizer would receive the European marketing rights. Isavuconazole was approved in the US in March 2015 and in the EU in October 2015.
BAL30072 is an intravenously administered monosulfactam antibiotic with a bactericidal effect against infections with multi-resistant gram-negative bacteria, which is currently in phase 1 of clinical development. The drug candidate showed in vitro and in vivo activity against gram-negative pathogens such as multi-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. The active ingredient has robust activity against bacteria that produce antibiotic-deactivating enzymes such as metallo-beta-lactamases. BAL30072 showed synergistic or additive activity in connection with antibiotics from the class of carbapenems. In previous phase 1 studies, the maximum tolerated dose for BAL30072 was determined; the limiting factor for the highest dose tested was temporarily elevated liver enzyme levels. In June 2013, Basilea signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop BAL30072. BARDA is a division of the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services. Under the agreement, BARDA will provide up to USD 89 million to finance the development of BAL30072.
BAL101553 is Basilea's experimental oncology compound in Phase 2a clinical development. In phase 1, in which the maximum tolerable dose was determined, the active ingredient showed the first signs of clinical anti-tumor effects. BAL101553 is a novel small molecule drug candidate with the potential to treat a variety of cancers, including types of tumors that do not respond to standard drugs. The active ingredient BAL27862 interacts with the microtubule network and stops tumor growth. This mechanism of action differs from that of conventional microtubule-attacking agents, such as. B. the taxanes. The intravenous as well as oral availability of BAL101553 allows flexible dosing. It also makes it easier to track different development scenarios depending on the indication and the potential combination therapies. Potential biomarkers are evaluated early in clinical development with the aim of optimizing treatment for those cancer patients who are most likely to respond to the substance. As part of Basilea's research and development approach, which focuses on the drug's molecular target, Basilea's work in cancer research complements that in anti-infectives. It is precisely immunocompromised cancer patients who are at high risk of contracting bacterial or fungal infections.
Web links
Individual evidence
- ↑ a b Basilea Pharmaceutica: Annual Report 2019 (pdf) Retrieved May 23, 2020 .
- ^ Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole), A Novel Treatment For Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients , PM Pfizer, July 20, 2017, accessed July 26, 2017